From: Assessing clinical trial failure risk factors and reasons in gastric cancer
Failed (N = 42) | Completed (N = 247) | Active (N = 262) | Good terminated (N = 16) | P-value | |
---|---|---|---|---|---|
Phase | 0.463 | ||||
Phase II | 33 (78.57%) | 184 (74.49%) | 192 (73.38%) | 11 (68.75%) | |
Phase III | 9 (21.43%) | 63 (25.51%) | 70 (26.72%) | 5 (31.25%) | |
Start year | < 0.001 | ||||
2007 | 2 (4.76%) | 25 (10.12%) | 1 (0.38%) | 1 (6.25%) | |
2008 | 3 (7.14%) | 31 (12.55%) | 1 (0.38%) | 1 (6.25%) | |
2009 | 4 (9.52%) | 28 (11.34%) | 1 (0.38%) | 0 | |
2010 | 2 (4.76%) | 23 (9.31%) | 1 (0.38%) | 0 | |
2011 | 5 (11.90%) | 28 (11.34%) | 2 (0.76%) | 3 (18.75%) | |
2012 | 7 (16.67%) | 27 (10.93%) | 2 (0.76%) | 3 (18.75%) | |
2013 | 4 (9.52%) | 21 (8.50%) | 11 (4.20%) | 2 (12.50%) | |
2014 | 3 (7.14%) | 17 (6.88%) | 7 (2.67%) | 3 (18.75%) | |
2015 | 4 (9.52%) | 22 (8.91%) | 12 (4.58%) | 0 | |
2016 | 1 (2.38%) | 3 (1.21%) | 23 (8.78%) | 0 | |
2017 | 5 (11.90%) | 14 (5.67%) | 38 (14.50%) | 2 (12.50%) | |
2018 | 2 (4.76%) | 6 (2.43%) | 43 (16.41%) | 1 (6.25%) | |
2019 | 0 | 2 (0.81%) | 59 (22.52%) | 0 | |
2020 | 0 | 0 | 61 (23.28%) | 0 | |
Treatment | < 0.001 | ||||
Drug | 30 (71.43%) | 186 (75.30%) | 153 (58.40%) | 14 (87.50%) | |
Device | 4 (9.52%) | 20 (8.10%) | 19 (7.25%) | 0 | |
Genetic | 8 (19.05%) | 32 (12.96%) | 71 (27.10%) | 1 (6.25%) | |
Radiation | 0 | 8 (3.24%) | 8 (3.05%) | 1 (6.25%) | |
Other | 0 | 1 (0.4%) | 11 (4.20%) | 0 | |
Sponsor | 0.356 | ||||
NIH | 2 (4.76%) | 21 (8.54%) | 11 (4.20%) | 0 | |
Industry | 20 (47.62%) | 106 (42.91%) | 125 (47.71%) | 6 (37.50%) | |
Other | 20 (47.62%) | 120 (48.58%) | 126 (48.09%) | 10 (62.50%) | |
Multi-centre | 0.062 | ||||
No | 15 (35.71%) | 132 (53.44%) | 123 (46.95%) | 5 (31.25%) | |
Yes | 27 (64.29%) | 115 (46.56%) | 139 (53.05%) | 11 (68.75%) | |
Multi-country | 0.093 | ||||
No | 29 (69.05%) | 205 (83.00%) | 202 (77.10%) | 11 (68.75%) | |
Yes | 13 (30.95%) | 42 (17.00%) | 60 (23.90%) | 5 (31.25%) | |
Anticipated accrual | 123.21 (132.80) | 159.67 (202.20) | 237.57 (268.70) | 209.94 (207.19) | 0.001 |
Duration | 36.36 (24.34) | 46.48 (23.41) | 43.40 (26.10) | 34.38 (15.25) | 0.363 |